|
| 37941406 | Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase. | Haematologica | 2024 |
| 35169231 | Macrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux. | Commun Biol | 2022 |
| 35668135 | The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness. | Nat Cell Biol | 2022 |
| 31857370 | Novel L-nucleoside analogue, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia. | Haematologica | 2021 |
| 34292323 | Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. | Blood | 2021 |
| 32299104 | Mitochondrial carrier homolog 2 is necessary for AML survival. | Blood | 2020 |
| 32416059 | Disrupting Mitochondrial Copper Distribution Inhibits Leukemic Stem Cell Self-Renewal. | Cell Stem Cell | 2020 |
| 32269163 | The mitochondrial peptidase, neurolysin, regulates respiratory chain supercomplex formation and is necessary for AML viability. | Sci Transl Med | 2020 |
| 30573504 | The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia. | Haematologica | 2019 |
| 29884901 | Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia. | Leukemia | 2019 |
| 31617661 | Global Interactome Mapping of Mitochondrial Intermembrane Space Proteases Identifies a Novel Function for HTRA2. | Proteomics | 2019 |
| 31173706 | The Mitochondrial Transacylase, Tafazzin, Regulates AML Stemness by Modulating Intracellular Levels of Phospholipids. | Cell Stem Cell | 2019 |
| 29518628 | AML refractory to primary induction with Ida-FLAG has a poor clinical outcome. | Leuk Res | 2018 |
| 28283480 | Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML. | Blood | 2017 |
| 26732203 | Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells. | Leuk Lymphoma | 2016 |
| 26624983 | Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism. | Oncotarget | 2016 |
| 27734609 | A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. | Cancer Med | 2016 |
| 27587383 | Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells. | Haematologica | 2016 |
| 27391350 | A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia. | Oncotarget | 2016 |
| 25820141 | Mitochondrial DNA damage by bleomycin induces AML cell death. | Apoptosis | 2015 |
| 26185171 | Increased pressure alters plasma membrane dynamics and renders acute myeloid leukemia cells resistant to daunorubicin. | Haematologica | 2015 |
| 26077472 | Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death. | Cancer Res | 2015 |
| 26058080 | Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia. | Cancer Cell | 2015 |
| 25832785 | Select microtubule inhibitors increase lysosome acidity and promote lysosomal disruption in acute myeloid leukemia (AML) cells. | Apoptosis | 2015 |
| 25998464 | Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells. | Apoptosis | 2015 |
| 25631767 | AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. | Blood | 2015 |
| 24273151 | Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. | Am J Hematol | 2014 |
| 24871339 | A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity. | PLoS One | 2014 |
| 24723613 | Mapping the cellular response to small molecules using chemogenomic fitness signatures. | Science | 2014 |
| 23318959 | Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide's anti-leukemic activity. | Leukemia | 2013 |
| 23520503 | Metabolic adaptation to chronic inhibition of mitochondrial protein synthesis in acute myeloid leukemia cells. | PLoS One | 2013 |
| 23202731 | Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors. | J Clin Invest | 2013 |
| 22683301 | A phase I study of the metal ionophore clioquinol in patients with advanced hematologic malignancies. | Clin Lymphoma Myeloma Leuk | 2012 |
| 22957033 | Suppression of cancer progression by MGAT1 shRNA knockdown. | PLoS One | 2012 |
| 21220410 | The tricyclic antidepressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases: in vitro and in silico evidence. | Mol Pharmacol | 2011 |
| 22009536 | Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers. | Cancer Res | 2011 |
| 22094260 | Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. | Cancer Cell | 2011 |
| 21513881 | Rerouting chlorambucil to mitochondria combats drug deactivation and resistance in cancer cells. | Chem Biol | 2011 |
| 21406729 | Inhibition of SREBP1 sensitizes cells to death ligands. | Oncotarget | 2011 |
| 20075161 | The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. | Blood | 2010 |
| 20644115 | The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells. | Blood | 2010 |
| 20348394 | The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. | Blood | 2010 |
| 20053768 | Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. | Mol Cancer Ther | 2010 |
| 19293189 | Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. | Cancer Res | 2009 |
| 18701493 | Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. | Cancer Res | 2008 |
| 19001437 | A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. | Mol Cancer Ther | 2008 |
| 18502826 | Cyproheptadine displays preclinical activity in myeloma and leukemia. | Blood | 2008 |
| 17505076 | Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. | J Natl Cancer Inst | 2007 |
| 17804746 | A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis. | Cancer Res | 2007 |
| 16489043 | Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. | Cancer Res | 2006 |